Ilaris®

Understanding Ilaris® 

Ilaris® (canakinumab) is a monoclonal antibody that targets interleukin-1 beta (IL-1β), a key driver of inflammation in certain autoimmune and autoinflammatory diseases. By inhibiting IL-1β, Ilaris® helps reduce inflammation and prevent disease flares in patients with rare and severe inflammatory conditions.

How Ilaris® Works:

• Blocks IL-1β, reducing excessive inflammation
• Prevents disease flares in IL-1β-mediated autoinflammatory conditions
• Provides long-term symptom relief for patients with inflammatory diseases

FDA Approvals:

• June 17, 2009: Approved for Cryopyrin-Associated Periodic Syndromes (CAPS)
• 2013: Expanded approval for Systemic Juvenile Idiopathic Arthritis (SJIA)
• 2016: Expanded approval for Adult-Onset Still’s Disease (AOSD) and Familial Mediterranean Fever (FMF)
• 2020: Expanded approval for gout flares

For more information, please visit the Ilaris® patient website and speak with your healthcare provider to determine if Ilaris® is the right treatment option for you.